Medical Facilities (DR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
7 May, 2026Executive summary
Facility service revenue rose 10.8% year-over-year to $67.1 million for Q1 2026, driven by favorable payer mix and higher orthopedic and spine procedure volumes.
Income from operations increased 17.6% to $12.8 million, and EBITDA grew 13.8% to $15.7 million compared to Q1 2025.
Completed the sale of a 64% ownership interest in Oklahoma Spine Hospital for $46 million in January 2026, strengthening the balance sheet.
Returned $3.8 million to shareholders through repurchase of 318,400 shares under the NCIB.
Continued a multi-year track record of capital returns to shareholders, including share repurchases.
Financial highlights
Net income from continuing operations surged 86.2% year-over-year to $13.1 million.
Basic EPS rose to $0.45 from $0.12, and fully diluted EPS increased to $0.21 from $0.12 year-over-year.
Consolidated cash balance at quarter end was $86.3 million, up from $43.4 million at December 31, 2025.
Net working capital increased to $67.1 million from $54 million sequentially.
Distributable cash flow (C$) declined 25.1% to C$6.8 million, while distributions per share rose 23.1% to C$0.089.
Outlook and guidance
Evaluating alternatives to further return capital to shareholders, with updates to be provided.
Strong cash position and financial flexibility support continued investment in hospitals and capital returns.
Focus remains on executing strategy, operational performance, and delivering long-term value.
Management highlights ongoing commitment to shareholder returns and operational investments.
Latest events from Medical Facilities
- Revenue and EBITDA rose on strong procedure mix, with major capital returned to shareholders.DR
Q2 2026 - Double-digit growth, strong liquidity, and active share buybacks drive value amid rising healthcare demand.DR
Investor update - Delivers strong financials and shareholder returns through high-quality specialty surgical hospitals.DR
Investor presentation - Strong revenue and earnings growth, major asset sales, and buybacks boosted shareholder returns.DR
Q4 2025 - Q2 saw SFSH headwinds but strong net income growth and new $40M credit secured.DR
Q2 2025 - Revenue and EBITDA rose on strong case volumes; PPP loan forgiveness to boost Q3.DR
Q2 2024 - Q3 net income up 263% and revenue up 11.2%, driven by PPP loan forgiveness and case growth.DR
Q3 2024 - Revenue and EBITDA stable, net income up, and $44.3M returned to shareholders via buybacks.DR
Q1 2025 - Net income nearly doubled in 2024, fueled by asset sales and robust capital returns.DR
Q4 2024